
Enrolled
N=6724
Randomized
n=2492
OM 40 mg/AML 10 mg
n=628
OM 40 mg/HCTZ 25 mg
n=637
AML 10 mg/HCTZ 25 mg
n=600
OM 40 mg/AML 10 mg/
HCTZ 25 mg
n=627
Discontinued
n=71 (11.3%)
Adverse events
n=22 (3.5%)
Lost to follow-up
n=15 (2.4%)
Discontinued
n=106 (16.6%)
Adverse events
n=46 (7.2%)
Lost to follow-up
n=17 (2.7%)
Discontinued
n=88 (14.7%)
Adverse events
n=38 (6.3%)
Lost to follow-up
n=21 (3.5%)
Discontinued
n=111 (17.7%)
Adverse events
n=48 (7.7%)
Lost to follow-up
n=26 (4.1%)
Completed
n=557 (88.7%)
Completed
n=531 (83.4%)
Completed
n=512 (85.3%)
Completed
n=516 (82.3%)
Entered Open-Label
Extension Period
N=2112
OM 40 mg/AML 5 mg/
HCTZ 12.5 mg
n=869
OM 40 mg/AML 5 mg/
HCTZ 25 mg
n=246
OM 40 mg/AML 10 mg/
HCTZ 12.5 mg
n=239
OM 40 mg/AML 10 mg/
HCTZ 25 mg
n=758
Discontinued
n=157 (18.1%)
Adverse events
n=76 (8.7%)
Lost to follow-up
n=23 (2.6%)
Discontinued
n=32 (13.0%)
Adverse events
n=9 (3.7%)
Lost to follow-up
n=9 (3.7%)
Discontinued
n=28 (11.7%)
Adverse events
n=10 (4.2%)
Lost to follow-up
n=4 (1.7%)
Discontinued
n=99 (13.1%)
Adverse events
n=32 (4.2%)
Lost to follow-up
n=19 (2.5%)
Completed
n=712 (81.9%)
Completed
n=214 (87.0%)
Completed
n=211 (88.3%)
Completed
n=659 (86.9%)